Fractyl Health gains on early data from weight management device trial
Shares of drug developer Fractyl Health GUTS.O rise 6.7% to $1.27 premarket
Co says early-stage data shows its weight management device Revita helps maintain weight in patients after they discontinued taking weight-loss drugs
One month post-procedure, seven patients experienced an average weight regain of just 1.2%, compared with the ~3% typically observed at this time period after GLP-1 discontinuation based on prior clinical studies - GUTS
Co expects to announce additional data from the study during Q3 of this year
Shares of the company have fallen 42.2% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Big Tech’s AI Data Center Power Demands Trigger $15B PJM Auction and a Nuclear SMR Boom

Tradingkey







